Abstract

Prostate cancer (PC) is one of the most common cancers among men worldwide, and advanced PCs, such as locally advanced PC (LAPC) and castration-resistant PC (CRPC), present the greatest challenges in clinical management. Current indicators have limited capacity to predict the disease course; therefore, better prognostic markers are greatly needed. In this study, we performed a bioinformatic analysis of The Cancer Genome Atlas (TCGA) datasets, including RNA-Seq data from the prostate adenocarcinoma (PRAD; n = 55) and West Coast Dream Team – metastatic CRPC (WCDT-MCRPC; n = 84) projects, to evaluate the transcriptome changes associated with progression-free survival (PFS) for LAPC and CRPC, respectively. We identified the genes whose expression was positively/negatively correlated with PFS. In LAPC, the genes with the most significant negative correlations were ZC2HC1A, SQLE, and KIF11, and the genes with the most significant positive correlations were SOD3, LRRC26, MIR22HG, MEG3, and MIR29B2CHG. In CRPC, the most significant positive correlations were found for BET1, CTAGE5, IFNGR1, and GIMAP6, and the most significant negative correlations were found for CLPB, PRPF19, ZNF610, MPST, and LINC02001. In addition, we performed a gene network interaction analysis using STRINGdb, which revealed a significant relationship between genes predominantly involved in the cell cycle and characterized by upregulated expression in early recurrence. Based on the results, we propose several genes that can be used as potential prognostic markers.

Highlights

  • Prostate cancer (PC) is the second most common cancer in men worldwide (Rawla, 2019)

  • This study aimed to analyze the transcriptome profiles of Locally advanced PC (LAPC) and castration-resistant PC (CRPC) based on the RNA-Seq data from the prostate adenocarcinoma (PRAD) and West Coast Dream Team – metastatic CRPC (WCDT-MCRPC) projects in The Cancer Genome Atlas (TCGA), respectively

  • Using PRAD and WCDT-MCRPC datasets, we analyzed changes of the relative gene expression associated with progression-free survival (PFS) and found 889 genes for the LAPC and 1,889 genes for CRPC with the p < 0.05 according to the QLF test (Supplementary Tables S1 and S2)

Read more

Summary

Introduction

Prostate cancer (PC) is the second most common cancer in men worldwide (Rawla, 2019). Advanced PC presents as locally advanced and castration-resistant tumors. Advanced PC (LAPC) is characterized by the spread of the tumor beyond the prostate capsule and is more aggressive than localized PC. Androgen deprivation therapy aimed at reducing the level of circulating testosterone is Transcriptomic Profiles of Advanced PC often used in LAPC treatment (Yap et al, 2016). Despite rapid patient responses to this therapy, after 18–36 months, the disease frequently progresses to castration-resistant PC (CRPC; Yap et al, 2016). Metastatic CRPC is a prognostically unfavorable disease that requires regular systematic examination and monitoring and significantly impairs quality of life

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call